2.62
Sl Science Holding Ltd Aktie (SLBT) Neueste Nachrichten
SL Science Holding Ltd (SLBT) Live Share Price, Invest From India - INDmoney
Morning Market Movers: RARE, BIAF, TLYS, SNOW See Big Swings - RTTNews
12 Health Care Stocks Moving In Thursday's Pre-Market Session - Benzinga
NetApp, Hewlett Packard Enterprise And Other Big Stocks Moving Lower In Thursday’s Pre-Market Session - Benzinga
Why Snowflake Shares Are Trading Higher By Over 24%; Here Are 20 Stocks Moving Premarket - Benzinga
SL Science Rings Nasdaq Bell, Marks First Quarter as Public Company and Advances γδ T Cell Therapy Platform - Quiver Quantitative
Johnson Lau Steps Down as VP of Finance at SL Science Holding Ltd - Kalkine Media
SL Science Holding Discloses Resignation of Vice President of Finance - TipRanks
SL Science (SLBT) finance VP steps down with no insider trades - Stock Titan
SL Science (SLBT) finance VP to step down Aug. 31 - Stock Titan
SL Science licensor files exosome drug master file with FDA - Investing.com India
SL Science Highlights New FDA Drug Master File for GDT Cell-Derived Exosomes, Expanding the Regulatory Foundation of its Platform - The Manila Times
A new FDA filing covers exosomes; studies indicate they can cross the blood-brain barrier - Stock Titan
SL Science Holding Ltd Switches Audit Firm to TAAD LLP in Late August 2026 - TipRanks
SL Science Holding Limited Ordinary Shares (NASDAQ: SLBT) Stock Price, News & Analysis - Kalkine
SL Science Holding (SLBT) Stock May Be Fully Priced Even After A 74% Fall - Yahoo Finance
SL Science Holding Ord Shs (SLBT) Technical Analysis: Support, Resistance, Indicators & Moving Averages - tradingkey.com
SL Science Holding Ltd SEC Filing (Aug 13, 2026) - Stock Titan
Upcoming & Recent IPO'sIPOs Calendar - Yahoo Finance
RBGLY Stock Price and Chart — OTC:RBGLY - TradingView
SL Science Leadership Co-Authors Peer-Reviewed Framework for Clinical Development of γδ T Cell Therapy in Glioblastoma - The Manila Times
SL Science Holding Limited Announces Publication of Peer-Reviewed Framework for γδ T Cell Therapy in Glioblastoma - Quiver Quantitative
Brain Cancer Cell Therapy Trials Must Track Cells, Review Says - Stock Titan
AbCellera Stock Soars 30% After Menopause Drug ABCL635 Hits Phase 2 Success In Hot Flash Trial Results - International Business Times Australia
Upcoming and recent IPOs – IPOs calendar - Yahoo Finance UK
Operating expenses (excl. COGS) of SL Science Holding Limited – NASDAQ:SLBT - TradingView
SL Science Holding Ord Shs (SLBT) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
12 Health Care Stocks Moving In Monday's Intraday Session - Benzinga
SL Science Holding (NASDAQ: SLBT) files to register resale of 1.04M shares - Stock Titan
Saol Therapeutics Announces the Acceptance of Resubmission of SL1009 (DCA) by the FDA with PDUFA Date of Dec. 30, 2026 - Yahoo Finance
SL Science Holding Ord Shs (SLBT) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
SLBT|SL Science Holding Ord Shs|Price:3.200|Chg%:+0.555 - TradingKey
SL Science Holding Ord Shs (SLBT) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
SL Science Holding Ord Shs (SLBT) Cash Flow - TradingKey
SL Science Holding Ord Shs (SLBT) Valuation: PE, PB & Fair Value Analysis - TradingKey
SL Science Holding Ord Shs (SLBT) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - tradingkey.com
Kwo Liang Chen Net Worth (2026) - GuruFocus
SLBT|SL Science Holding Ord Shs|Price:3.120|Chg%:-0.050 - TradingKey
SLBT|SL Science Holding Ord Shs|Price:2.620|Chg%:-0.500 - TradingKey
Ching Dong Wang Net Worth (2026) - GuruFocus
Mingche Liu Net Worth (2026) - GuruFocus
The Second Battlefield for Solid Tumor CAR-T: A Global Race in the Intracranial Arena -- Who Is Leading? - Yahoo Finance
Lok Sang Leung Net Worth (2026) - GuruFocus
SL Science presents glioblastoma treatment data at WCP 2026 - Investing.com UK
SL Science presents glioblastoma treatment data at WCP 2026 By Investing.com - Investing.com South Africa
Trevi Therapeutics Shares Surge 13% as Biopharma Investors Cheer Cough Drug Data at London Conference - International Business Times Australia
SL Science Holding Limited Exhibits Breakthrough Gamma Delta T Cell Therapy for Glioblastoma at 2026 World Congress of Basic and Clinical Pharmacology - marketscreener.com
SL Science Announces Successful Exhibition of Breakthrough Brain Cancer Therapy Research at the 2026 World Congress of Basic and Clinical Pharmacology - The Manila Times
SL Science Showcases Preclinical Gamma Delta T Cell Study Demonstrating Glioblastoma Elimination at WCP 2026 - Quiver Quantitative
Preclinical γδ T cells eradicated a brain tumor by day 26 at highest dose - Stock Titan
4DMedical Shares Plunge 15.57% to $3.20 as Volatile ASX Healthcare Stock's Wild Ride Continues This Week - International Business Times Australia
Ericsson, Q32 Bio and other big stocks moving lower in Tuesday’s pre-market session - MSN
Ericsson, Q32 Bio And Other Big Stocks Moving Lower In Tuesday’s Pre-Market Session - Sahm
SL Science seeks US orphan drug designation for γδ T-cell therapy - bioworld.com
Net current asset value per share of SL Science Holding Limited – BOATS:SLBT - TradingView
Number of employees of SL Science Holding Limited – NASDAQ:SLBT - TradingView
Gross margin % of SL Science Holding Limited – NASDAQ:SLBT - TradingView
Price to book ratio of SL Science Holding Limited – NASDAQ:SLBT - TradingView
Net margin % of SL Science Holding Limited – NASDAQ:SLBT - TradingView
SL Science Holding Limited (SLBT-Q) Stock Price and News - The Globe and Mail
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):